Grant of Options

RNS Number : 1263U

Renalytix AI PLC

21 November 2019

 

Renalytix AI plc

("RenalytixAI" or the "Company")

Grant of Options

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that the Remuneration Committee agreed to issue options over a total of 50,000 ordinary shares of £0.0025 each in the capital of the Company ("Share Options").

The Share Options have been issued in line with the Company's existing share option plan to Chirag Parikh, a Director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Chirag Parikh on 1 November 2018, and combined the number of ordinary shares held under option by Chirag Parikh is 130,724, representing 0.22% of the existing issued ordinary share capital of the Company.

The Share Options are exercisable in 12 equal quarterly instalments over 36 months, in line with options previously granted to the Company's Directors under the Company's existing share option plan, and at an exercise price of £2.51.

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)		Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)			Tel: [phone]
Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease. It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD¹. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

Notes

1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chirag Parikh
2	Reason for the notification
a)	Position/status	Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	RenalytixAI plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.0025 ("Ordinary Shares") ISIN Code: GB00BYWL4Y04
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 251p 50,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	20 November 2019
f)	Place of the transaction	Outside trading venue - off market

 

END

 

 

MSCCKKDPOBDDFDB